MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Iovance Biotherapeutics DPO Ratio 2011-2026 | IOVA
Annual DPO Ratio Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.3 | 119 | 10.6 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.6 K | 52.3 | 3.57 K |
Quarterly DPO Ratio Iovance Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75 | 48.7 | 51.4 | - | 75.4 | 67.1 | 370 | - | 530 | 1.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.4 K | 48.7 | 327 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Regeneron Pharmaceuticals
REGN
|
195 | $ 742.1 | -1.93 % | $ 77.6 B |  USA |
 |
AbbVie
ABBV
|
65.5 | $ 211.9 | 0.37 % | $ 375 B | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
97.9 | $ 26.28 | -0.34 % | $ 473 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
Rhythm Pharmaceuticals
RYTM
|
246 | $ 77.56 | -5.31 % | $ 5.04 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
35.1 | $ 12.27 | -12.11 % | $ 1.86 B | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
13.3 | $ 5.36 | 7.96 % | $ 383 M | USA |
 |
Silence Therapeutics plc
SLN
|
10.6 | $ 4.92 | -7.34 % | $ 622 M | Britain |
 |
SELLAS Life Sciences Group
SLS
|
10 K | $ 4.47 | -9.69 % | $ 487 M | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 1.08 | -1.38 % | $ 22.2 M | Israel |
 |
Summit Therapeutics
SMMT
|
84.9 K | $ 16.59 | -3.88 % | $ 12.4 B | Britain |